C-X-C motif receptor 7 in gastrointestinal cancer (Review)
- Authors:
- Hwan‑Jung Yun
- Hyewon Ryu
- Yoon Seok Choi
- Ik‑Chan Song
- Deog‑Yeon Jo
- Samyong Kim
- Hyo Jin Lee
-
Affiliations: Division of Hematology/Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon 301‑721, Republic of Korea - Published online on: June 22, 2015 https://doi.org/10.3892/ol.2015.3407
- Pages: 1227-1232
This article is mentioned in:
Abstract
|
Bachelerie F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH, Locati M, Luster AD, et al: International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev. 66:1–79. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HJ, Song IC, Yun HJ, Jo DY and Kim S: CXC chemokines and chemokine receptors in gastric cancer: From basic findings towards therapeutic targeting. World J Gastroenterol. 20:1681–1693. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Balkwill FR: The chemokine system and cancer. J Pathol. 226:148–157. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Lee HJ and Jo DY: The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer. Histol Histopathol. 27:1155–1161. 2012.PubMed/NCBI | |
|
Libert F, Parmentier M, Lefort A, Dumont JE and Vassart G: Complete nucleotide sequence of a putative G protein coupled receptor: RDC1. Nucleic Acids Res. 18:19171990. View Article : Google Scholar : PubMed/NCBI | |
|
Sánchez-Martín L, Sánchez-Mateos P and Cabañas C: CXCR7 impact on CXCL12 biology and disease. Trends Mol Med. 19:12–22. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tarnowski M, Liu R, Wysoczynski M, Ratajczak J, Kucia M and Ratajczak MZ: CXCR7: A new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells. Eur J Haematol. 85:472–483. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, et al: Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med. 187:2009–2021. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Maksym RB, Tarnowski M, Grymula K, Tarnowska J, Wysoczynski M, Liu R, Czerny B, Ratajczak J, Kucia M and Ratajczak MZ: The role of stromal-derived factor-1 - CXCR7 axis in development and cancer. Eur J Pharmacol. 625:31–40. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A, Nagler A, Lapidot T, Thelen M and Alon R: A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. J Leukoc Biol. 84:1130–1140. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Infantino S, Moepps B and Thelen M: Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J Immunol. 176:2197–2207. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mazzinghi B, Ronconi E, Lazzeri E, Sagrinati C, Ballerini L, Angelotti ML, Parente E, Mancina R, Netti GS, Becherucci F, et al: Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J Exp Med. 205:479–490. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Naumann U, Cameroni E, Pruenster M, Mahabaleshwar H, Raz E, Zerwes HG, Rot A and Thelen M: CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One. 5:e91752010. View Article : Google Scholar : PubMed/NCBI | |
|
Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold ME, Sunshine MJ, Littman DR, Kuo CJ, et al: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 203:2201–2213. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Eva C and Sprengel R: A novel putative G protein-coupled receptor highly expressed in lung and testis. DNA Cell Biol. 12:393–399. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Libert F, Parmentier M, Lefort A, Dinsart C, Van Sande J, Maenhaut C, Simons MJ, Dumont JE and Vassart G: Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science. 244:569–572. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Tripathi V, Verma R, Dinda A, Malhotra N, Kaur J and Luthra K: Differential expression of RDC1/CXCR7 in the human placenta. J Clin Immunol. 29:379–386. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J: CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 29:709–722. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Keeley EC, Mehrad B and Strieter RM: CXC chemokines in cancer angiogenesis and metastases. Adv Cancer Res. 106:91–111. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Raggo C, Ruhl R, McAllister S, Koon H, Dezube BJ, Früh K and Moses AV: Novel cellular genes essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus. Cancer Res. 65:5084–5095. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A, Kleer CG, Essner JJ, Nasevicius A, Luker GD, et al: CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci USA. 104:15735–15740. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R and Taichman RS: The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem. 283:4283–4294. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Berahovich RD, Zabel BA, Penfold ME, Lewén S, Wang Y, Miao Z, Gan L, Pereda J, Dias J, Slukvin II, et al: CXCR7 protein is not expressed on human or mouse leukocytes. J Immunol. 185:5130–5139. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Bennani-Baiti IM, Cooper A, Lawlor ER, Kauer M, Ban J, Aryee DN and Kovar H: Intercohort gene expression co-analysis reveals chemokine receptors as prognostic indicators in Ewing's sarcoma. Clin Cancer Res. 16:3769–3778. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Tarnowski M, Grymula K, Reca R, Jankowski K, Maksym R, Tarnowska J, Przybylski G, Barr FG, Kucia M and Ratajczak MZ: Regulation of expression of stromal-derived factor-1 receptors: CXCR4 and CXCR7 in human rhabdomyosarcomas. Mol Cancer Res. 8:1–14. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Van Rechem C, Rood BR, Touka M, Pinte S, Jenal M, Guérardel C, Ramsey K, Monté D, Bégue A, Tschan MP, et al: Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1). J Biol Chem. 284:20927–20935. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Calatozzolo C, Canazza A, Pollo B, Di Pierro E, Ciusani E, Maderna E, Salce E, Sponza V, Frigerio S, Di Meco F, et al: Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biol Ther. 11:242–253. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hattermann K, Held-Feindt J, Lucius R, Müerköster SS, Penfold ME, Schall TJ and Mentlein R: The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res. 70:3299–3308. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mehra R, Serebriiskii IG, Burtness B, Astsaturov I and Golemis EA: Aurora kinases in head and neck cancer. Lancet Oncol. 14:e425–e435. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Miyazaki H, Takabe K and Yeudall WA: Chemokines, chemokine receptors and the gastrointestinal system. World J Gastroenterol. 19:2847–2863. 2013.PubMed/NCBI | |
|
Yeudall WA and Miyazaki H: Chemokines and squamous cancer of the head and neck: Targets for therapeutic intervention? Expert Rev Anticancer Ther. 7:351–360. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Xia J, Wang J, Chen N, Dai Y, Hong Y, Chen X and Cheng B: Expressions of CXCR7/ligands may be involved in oral carcinogenesis. J Mol Histol. 42:175–180. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Maussang D, Mujić-Delić A, Descamps FJ, Stortelers C, Vanlandschoot P, Stigter-van Walsum M, Vischer HF, van Roy M, Vosjan M, Gonzalez-Pajuelo M, et al: Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo. J Biol Chem. 288:29562–29572. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ge XS, Ma HJ, Zheng XH, Ruan HL, Liao XY, Xue WQ, Chen YB, Zhang Y and Jia WH: HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway. Cancer Sci. 104:1675–1682. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Tachezy M, Zander H, Gebauer F, von Loga K, Pantel K, Izbicki JR and Bockhorn M: CXCR7 expression in esophageal cancer. J Transl Med. 11:2382013. View Article : Google Scholar : PubMed/NCBI | |
|
Iwakiri S, Mino N, Takahashi T, Sonobe M, Nagai S, Okubo K, Wada H, Date H and Miyahara R: Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer. 115:2580–2593. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhi Y, Chen J, Zhang S, Chang X, Ma J and Dai D: Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression. Dig Dis Sci. 57:650–659. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Xu H, Wu Q, Dang S, Jin M, Xu J, Cheng Y, Pan M, Wu Y, Zhang C and Zhang Y: Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One. 6:e273992011. View Article : Google Scholar : PubMed/NCBI | |
|
Guillemot E, Karimdjee-Soilihi B, Pradelli E, Benchetrit M, Goguet-Surmenian E, Millet MA, Larbret F, Michiels JF, Birnbaum D, Alemanno P, et al: CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Br J Cancer. 107:1944–1949. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Romain B, Hachet-Haas M, Rohr S, Brigand C, Galzi JL, Gaub MP, Pencreach E and Guenot D: Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. Mol Cancer. 13:582014. View Article : Google Scholar : PubMed/NCBI | |
|
Rupertus K, Sinistra J, Scheuer C, Nickels RM, Schilling MK, Menger MD and Kollmar O: Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer. Clin Exp Metastasis. 31:447–459. 2014. View Article : Google Scholar | |
|
Heckmann D, Maier P, Laufs S, Li L, Sleeman JP, Trunk MJ, Leupold JH, Wenz F, Zeller WJ, Fruehauf S, et al: The disparate twins: A comparative study of CXCR4 and CXCR7 in SDF-1α -induced gene expression, invasion and chemosensitivity of colon cancer. Clin Cancer Res. 20:604–616. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, et al: A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients. Int J Cancer. 135:379–390. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Kheirelseid EA, Miller N, Chang KH, Nugent M and Kerin MJ: Clinical applications of gene expression in colorectal cancer. J Gastrointest Oncol. 4:144–157. 2013.PubMed/NCBI | |
|
Wang L, Zhang X, Jia LT, Hu SJ, Zhao J, Yang JD, Wen WH, Wang Z, Wang T, Zhao J, et al: c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology. 59:1850–1863. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Xue TC, Chen RX, Han D, Chen J, Xue Q, Gao DM, Sun RX, Tang ZY and Ye SL: Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential. Exp Ther Med. 3:117–123. 2012.PubMed/NCBI | |
|
Xue TC, Han D, Chen RX, Zou JH, Wang Y, Tang ZY and Ye SL: High expression of CXCR7 combined with Alpha fetoprotein in hepatocellular carcinoma correlates with extra-hepatic metastasis to lung after hepatectomy. Asian Pac J Cancer Prev. 12:657–663. 2011.PubMed/NCBI | |
|
Zheng K, Li HY, Su XL, Wang XY, Tian T, Li F and Ren GS: Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J Exp Clin Cancer Res. 29:312010. View Article : Google Scholar : PubMed/NCBI | |
|
Monnier J, Boissan M, L'Helgoualc'h A, Lacombe ML, Turlin B, Zucman-Rossi J, Théret N, Piquet-Pellorce C and Samson M: CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur J Cancer. 48:138–148. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ghanem I, Riveiro ME, Paradis V, Faivre S, de Parga PM and Raymond E: Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis. Am J Transl Res. 6:340–352. 2014.PubMed/NCBI | |
|
Xue TC, Jia QA, Bu Y, Chen RX, Cui JF, Tang ZY and Ye SL: CXCR7 correlates with the differentiation of hepatocellular carcinoma and suppresses HNF4α expression through the ERK pathway. Oncol Rep. 32:2387–2396. 2014.PubMed/NCBI | |
|
Xue TC, Chen RX, Ren ZG, Zou JH, Tang ZY and Ye SL: Transmembrane receptor CXCR7 increases the risk of extrahepatic metastasis of relatively well-differentiated hepatocellular carcinoma through upregulation of osteopontin. Oncol Rep. 30:105–110. 2013.PubMed/NCBI | |
|
Hong TS, Ryan DP, Borger DR, Blaszkowsky LS, Yeap BY, Ancukiewicz M, Deshpande V, Shinagare S, Wo JY, Boucher Y, et al: A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable pancreatic ductal adenocarcinoma. Int J Radiat Oncol Biol Phys. 89:830–838. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Heinrich EL, Lee W, Lu J, Lowy AM and Kim J: Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med. 10:682012. View Article : Google Scholar : PubMed/NCBI | |
|
Guo JC, Li J, Yang YC, Zhou L, Zhang TP and Zhao YP: Oligonucleotide microarray identifies genes differentially expressed during tumorigenesis of DMBA-induced pancreatic cancer in rats. PLoS One. 8:e829102013. View Article : Google Scholar : PubMed/NCBI | |
|
Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR and Bockhorn M: Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J Surg Oncol. 104:140–145. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA and Hidalgo M: Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Neoplasia. 14:690–701. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Roy I, Zimmerman NP, Mackinnon AC, Tsai S, Evans DB and Dwinell MB: CXCL12 chemokine expression suppresses human pancreatic cancer growth and metastasis. PLoS One. 9:e904002014. View Article : Google Scholar : PubMed/NCBI | |
|
Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, Closset J, Devière J, Salmon I and Van Laethem JL: High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer. 100:1444–1451. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Yao X, Zhou L, Han S and Chen Y: High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer. J Int Med Res. 39:1253–1264. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zabel BA, Wang Y, Lewén S, Berahovich RD, Penfold ME, Zhang P, Powers J, Summers BC, Miao Z, Zhao B, et al: Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J Immunol. 183:3204–3211. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Luker KE, Gupta M and Luker GD: Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 23:823–834. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Duda DG, Kozin SV, Kirkpatrick ND, Xu L, Fukumura D and Jain RK: CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: An emerging sensitizer for anticancer therapies? Clin Cancer Res. 17:2074–2080. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Dai X, Xiong X, Wang L, Pan K, He L and Li H: Effects of CXCR7-shRNA lentiviral vector on the growth and invasiveness of human hepatoma carcinoma cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 33:994–998. 2013.(In Chinese). PubMed/NCBI | |
|
Ribas R, Ghazoui Z, Gao Q, Pancholi S, Rani A, Dunbier A, Dowsett M and Martin LA: Identification of chemokine receptors as potential modulators of endocrine resistance in oestrogen receptor-positive breast cancers. Breast Cancer Res. 16:4472014. View Article : Google Scholar : PubMed/NCBI | |
|
Walters MJ, Ebsworth K, Berahovich RD, Penfold ME, Liu SC, Al Omran R, Kioi M, Chernikova SB, Tseng D, Mulkearns-Hubert EE, et al: Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br J Cancer. 110:1179–1188. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Hou KL, Hao MG, Bo JJ and Wang JH: CXCR7 in tumorigenesis and progression. Chin J Cancer. 29:456–459. 2010. View Article : Google Scholar : PubMed/NCBI |
